Expectations are that Tesla could unveil a less expensive car at its investor day event Wednesday. Novavax stock sinks after the vaccine maker says there is 'substantial doubt' about its ability to continue operating through the year.
2 minExpectations are that Tesla could unveil a less expensive car at its investor day event Wednesday. Novavax stock sinks after the vaccine maker says there is 'substantial doubt' about its ability to continue operating through the year.
2 minThe agency's vaccine-advisory committee is looking at dueling products from Pfizer and GSK. Lots of money is at stake.
Long readArconic stock surged on report of a potential acquisition. Shares of Norwegian fell after the cruise operator provided earnings guidance for the first quarter and full year below estimates.
2 minThe Covid-19 vaccine maker will be forced to compete again the far-better-resourced Pfizer and Moderna, casting questions over its 2023 revenues.
3 minDentsply Sirona posted fourth-quarter adjusted earnings of 46 cents a share, while analysts had penciled in 32 cents a share.
1 minTroubles that were put off during the biotech’s pandemic-era boom, notably various intellectual property wrinkles, are now coming home to roost.
4 minFisker says it still expects to build and ship around 42,000 units in 2023. A report says Pfizer is in discussions to acquire biotechnology company Seagen.
2 minThe deal would strengthen Pfizer's lineup of cancer treatments, The Wall Street Journal reports.
4 minNew gaming processors boost chip maker’s sales. Also, Wall Street views on Shell, TJX, Etsy, PDC Energy, and Arcutis Biotherapeutics.
4 minShares of the biotech company fell early Thursday, wiping out gains from positive news around its cancer vaccine candidate, as fourth-quarter earnings missed expectations.
1 minThe company said it expects to complete a filing for FDA approval for the treatment by March, highlighting its lead in a competitive field.
2 minLegislation was meant to end the chokehold of 'biologics' by opening the path to cheaper copycats. It hasn't happened yet.
Long readThere will be significant changes to vaccine costs and access this year, write Cynthia Cox and Jen Kates.
Long readThe company and its partner Valneva have removed about half of the participants from the vaccine program, citing violations of ethical and scientific quality standards by a third-party operator at some locations.
3 minPfizer and McCormick have continued to fall in 2023 after big losses in 2022. Meanwhile, United Rentals and Nucor have continued their rallies.
4 min